16 Result(s)
within
Yasuo Suzuki
Colorectal Surgery
-
Article
Open AccessA review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation
Many clinical trials have been conducted for inflammatory bowel disease (IBD), so various clinical indices (CIs) and endoscopic indices (EIs) have also been evaluated. However, recently, with the progress of I...
-
Article
Open AccessA nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan
The mortality and risk factors of severe disease and death due to arterial and venous thromboembolism (ATE and VTE, respectively) in patients with inflammatory bowel disease (IBD) remain unclear, especially in...
-
Article
Open AccessAdrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
Adrenomedullin (AM) is a bioactive peptide having many pleiotropic effects, including mucosal healing and immunomodulation. AM has shown beneficial effects in rodent models and in preliminary study for patient...
-
Article
Open AccessEvidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants
Behçet's disease (BD) is an intractable systemic inflammatory disease characterized by four main symptoms: oral and genital ulcers and ocular and cutaneous involvement. The Japanese diagnostic criteria of BD c...
-
Article
Open AccessEffects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
Vedolizumab is a gut-selective humanized antibody that binds the α4β7 integrin. We evaluated efficacy and safety of vedolizumab in Japanese patients with moderate-to-severe Crohn’s disease (CD).
-
Article
Correction to: High-resolution melt analysis enables simple genoty** of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype
The correct name of the last author should be.
-
Article
Correction to: Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2015: an analysis of a nationwide survey
The authors would like to correct the errors in the publication of the original article.
-
Article
Open AccessCorrection to: Management of elderly ulcerative colitis in Japan
Management of elderly ulcerative colitis in Japan
-
Article
Open AccessManagement of elderly ulcerative colitis in Japan
Japan has the largest aging society, where many elderly people have intractable diseases including ulcerative colitis (UC). Along with the increasing total number of UC patients, the number of elderly UC patie...
-
Article
Open AccessCapsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case–control study
Capsule endoscopy can be used to identify the early stage of small bowel Crohn’s disease (CD). We evaluated significant small bowel capsule endoscopy (SBCE) findings that can lead to early diagnosis of CD.
-
Article
Open AccessNUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be test...
-
Article
Open AccessEvidence-based clinical practice guidelines for inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowle...
-
Article
Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
-
Article
Open AccessFour-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enroll...
-
Article
Open AccessFirst trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
Infliximab (IFX) is one of the treatments of choice for corticosteroid-refractory and corticosteroid-dependent ulcerative colitis (UC). A high serum trough level of IFX (TL) is reported to be associated with s...
-
Article
Open AccessEfficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Adalimumab is a fully human, monoclonal antibody against tumor necrosis factor that is approved in Western countries for the treatment of moderately to severely active ulcerative colitis (UC).
